Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that the first patient has been successfully dosed in the Phase III ...
In a Chinese trial, trastuzumab rezetecan induced a 73% response rate in previously treated HER2-mutant non-small cell lung cancer (NSCLC). The safety profile of the novel antibody-drug conjugate was ...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief ...
HER2 (also known as ERBB2) is a key oncogene in breast cancer and is found in 2–4% of patients with non-small-cell lung ...
Greater tumor-infiltrating lymphocyte density is associated with improved overall survival outcomes in patients with ...
Higher TIL levels predict better survival in early ERBB2-positive breast cancer, supporting treatment de-escalation for select patients.
T-DM1 reduced risk of invasive disease events and death compared with trastuzumab in HER2-positive early breast cancer with ...
Holdings announced its plans to advance the development of its proprietary Antibody Drug Conjugate (ADC) platform ...
Ronan J. Kelly, MD, MBA, discusses the targeted therapy options that have become available for patients with gastric, ...
Based on work Dr. Petrylak presented at ASCO 2024 looking at dose adjustment and efficacy of enfortumab vedotin, most ...
GU ASCO annual meeting featured a session on the ABCs of antibody drug conjugates and a presentation by Dr. Di Maria Jiang discussing the targeting of bladder cancer with antibody drug conjugates. Dr.
Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results